Quinolone Therapy for Gram-Negative Bacteremia
Oral quinolones (ciprofloxacin or levofloxacin) are appropriate for treatment of selected gram-negative bacteremia when susceptibility is demonstrated and clinical criteria for early IV-to-PO transition are met. [1,2]
Recommended quinolone regimens are based on uncomplicated gram-negative bloodstream infection step-down guidance and fluoroquinolone safety labeling. [2,3]
Medication Selection Algorithm
Quinolone therapy (ciprofloxacin or levofloxacin) is appropriate for gram-negative bacteremia in scenarios that meet all of the following requirements: [1,2]
- Demonstrated in vitro susceptibility of the bacteremia isolate to the quinolone agent. [1,2]
- Hemodynamic stability without vasopressor requirement. [2]
- Source control achieved. [1,2]
- No metastatic focus of infection attributable to bacteremia. [2]
- Ability to tolerate and absorb oral medications. [2]
- Absence of concerns for insufficient intestinal absorption when considering oral step-down. [1]
Quinolone therapy should be avoided for oral step-down in ESBL-producing Enterobacterales bacteremia when appropriate serum exposures cannot be achieved due to absorption concerns. [1]
Recommended Dosing for Quinolone Step-Down
UCSF gram-negative bloodstream infection adult IV-to-PO step-down guidance recommends the following oral dosing for normal renal function: [2]
- Ciprofloxacin 750 mg PO twice daily. [2]
- Levofloxacin 750 mg PO daily. [2]
Duration of Therapy With Quinolones
UCSF guidance recommends a typical total duration of 7 days of therapy (DOT), with day 1 counted from the first day of microbiologically active IV therapy. [2]
In a noninferiority randomized trial of uncomplicated gram-negative bacteremia, 7 days of antibiotic therapy was noninferior to 14 days in patients achieving clinical stability before day 7. [4]
Key Evidence Supporting Quinolone Use
IDSA guidance supports oral step-down to ciprofloxacin or levofloxacin for ESBL-producing Enterobacterales bloodstream infections when susceptibility is demonstrated, hemodynamic stability is present, reasonable source control has occurred, and concerns about insufficient intestinal absorption are absent. [1]
UCSF step-down guidance uses inclusion criteria that require at least 48 hours of microbiologically active IV therapy and at least 48 hours of clinical stability, which aligns with the setting in which oral step-down is feasible. [2]
Contraindications and Key Safety Limitations
Fluoroquinolones are contraindicated with: [3]
- Hypersensitivity to ciprofloxacin, any fluoroquinolone/quinolone antimicrobial agent, or any product component. [3]
Fluoroquinolone boxed-warning contraindications and limitations include: [5]
- Myasthenia gravis due to risk of exacerbation of muscle weakness. [5]
Fluoroquinolone safety labeling includes warnings for disabling and potentially serious adverse reactions, including tendon injury and peripheral neuropathy. [5]
Common Pitfalls to Avoid
Quinolones should not be selected for oral step-down when any of the following conditions are present: [2]
- Uncontrolled source, including retained infected line, hardware, device, or prosthesis. [2]
- Endovascular infection without a removable focus. [2]
- Necrotizing soft tissue infection requiring further debridement. [2]
- Undrained or undrainable abscess. [2]
- Metastatic infections from bacteremia including CNS infection, empyema, endocarditis, osteomyelitis, or septic arthritis. [2]
Quinolones should not be used for oral step-down in ESBL-producing Enterobacterales bacteremia when absorption is unreliable. [1]
Target Goals of Therapy
Oral quinolone step-down is intended to achieve treatment within uncomplicated bacteremia criteria, including: [2]
- No vasopressor requirement and normothermia without antipyretic medications for at least 48 hours. [2]
- Tolerance and ability to absorb oral medications. [2]
- Usual goal of a total 7-day duration for eligible uncomplicated gram-negative bacteremia. [2]